These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 33761040)
41. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515 [TBL] [Abstract][Full Text] [Related]
42. Preliminary results on response assessment using Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010 [TBL] [Abstract][Full Text] [Related]
53. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121 [TBL] [Abstract][Full Text] [Related]
54. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
56. Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist Satpati D; Vats K; Sharma R; Kameswaran M; Sarma HD; Dash A J Labelled Comp Radiopharm; 2019 Oct; 62(12):843-849. PubMed ID: 31378967 [TBL] [Abstract][Full Text] [Related]
57. Quality control and GMP synthesis of Assadi M; Dadgar H World J Nucl Med; 2020; 19(2):93-98. PubMed ID: 32939194 [TBL] [Abstract][Full Text] [Related]
58. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208 [TBL] [Abstract][Full Text] [Related]
59. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836 [TBL] [Abstract][Full Text] [Related]
60. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]